Sofinnova Investments, Inc.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1631134) · Explore on the interactive board
Sofinnova Investments, Inc. disclosed 53 US equity positions worth $1.9bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is NTRA at 22.5% of the reported book, followed by VERA, GMAB. The top ten holdings are 59.8% of the book, and the portfolio behaves like about 13 equal-weight positions. Versus the prior filing it opened 11 new positions, added to 12, reduced 17 and exited 19. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Sofinnova Investments, Inc. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 11 new, 12 added, 17 reduced, 19 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | NTRA Natera Inc | Healthcare | 22.5% | $420.8m | 1,550,280 | 0% | held |
| 2 | VERA Vera Therapeutics Inc | Healthcare | 6.4% | $119.9m | 2,793,987 | 0% | held |
| 3 | GMAB Genmab A/S | Healthcare | 5.9% | $111.1m | 4,045,215 | 438% | added |
| 4 | JAZZ Jazz Pharmaceuticals PLC | Healthcare | 4.7% | $88.0m | 365,341 | -39% | reduced |
| 5 | RAPP Rapport Therapeutics Inc | 4.2% | $79.4m | 1,904,408 | 0% | held | |
| 6 | Seaport Therapeutics Inc | 4.1% | $77.4m | 3,564,871 | – | new | |
| 7 | AVBP Arrivent BioPharma Inc | Healthcare | 3.1% | $58.9m | 1,696,752 | 0% | held |
| 8 | RARE Ultragenyx Pharmaceutical In | Healthcare | 3.1% | $57.3m | 1,717,505 | -45% | reduced |
| 9 | BIOA BioAge Labs Inc | 3.0% | $56.2m | 2,293,788 | 0% | held | |
| 10 | BMY Bristol-Myers Squibb Co | Healthcare | 2.7% | $50.5m | 876,970 | -56% | reduced |
| 11 | SUPN Supernus Pharmaceuticals | Healthcare | 2.6% | $48.2m | 1,036,328 | 9% | added |
| 12 | RYTM Rhythm Pharmaceuticals Inc | Healthcare | 2.4% | $45.3m | 408,027 | -9% | reduced |
| 13 | GILD Gilead Sciences Inc | Healthcare | 2.3% | $43.3m | 343,100 | – | new |
| 14 | UTHR United Therapeutics Corp Del | Healthcare | 2.2% | $41.4m | 76,489 | -52% | reduced |
| 15 | COGT Cogent Biosciences Inc | Healthcare | 2.1% | $40.1m | 1,035,148 | -51% | reduced |
| 16 | AXSM Axsome Therapeutics Inc. | Healthcare | 2.1% | $39.3m | 160,429 | -25% | reduced |
| 17 | IMTX Immatics N.V | Healthcare | 2.0% | $37.2m | 3,669,346 | 1% | added |
| 18 | DYN Dyne Therapeutics Inc | Healthcare | 2.0% | $36.8m | 1,658,384 | 1% | added |
| 19 | IMNM Immunome Inc | Healthcare | 1.9% | $36.5m | 1,720,316 | 1% | added |
| 20 | IDYA IDEAYA Biosciences Inc | Healthcare | 1.8% | $34.5m | 925,119 | -18% | reduced |
| 21 | ANAB Anaptysbio Inc | Healthcare | 1.8% | $33.3m | 493,536 | 99% | added |
| 22 | NKTR Nektar Therapeutics | Healthcare | 1.8% | $32.9m | 471,763 | -7% | reduced |
| 23 | PHVS Pharvaris N V | Healthcare | 1.6% | $30.5m | 881,299 | 8% | added |
| 24 | RCUS Arcus Biosciences Inc | Healthcare | 1.6% | $29.2m | 945,690 | 2% | added |
| 25 | INBX Inhibrx Biosciences Inc | Healthcare | 1.5% | $28.7m | 303,103 | -25% | reduced |
| 26 | BMRN BioMarin Pharmaceutical Inc | Healthcare | 1.1% | $20.5m | 358,568 | -54% | reduced |
| 27 | MANE Veradermics Inc | Healthcare | 1.0% | $18.3m | 148,993 | 103% | added |
| 28 | ALC Alcon AG | Healthcare | 0.9% | $17.2m | 255,824 | -65% | reduced |
| 29 | INSM Insmed Inc | Healthcare | 0.9% | $16.9m | 158,398 | -54% | reduced |
| 30 | EWTX Edgewise Therapeutics Inc | Healthcare | 0.8% | $15.5m | 380,923 | -1% | reduced |
| 31 | NRIX Nurix Therapeutics Inc | Healthcare | 0.7% | $12.7m | 524,098 | – | new |
| 32 | DSGN Design Therapeutics Inc | Healthcare | 0.7% | $12.5m | 865,135 | – | new |
| 33 | DFTX Definium Therapeutics Inc | Healthcare | 0.6% | $12.0m | 255,903 | -26% | reduced |
| 34 | TRAX First Tracks Biotherapeutics | 0.6% | $11.4m | 565,199 | – | new | |
| 35 | ABT Abbott Laboratories | Healthcare | 0.6% | $11.2m | 122,998 | – | new |
| 36 | IRON Disc Medicine Inc | Healthcare | 0.6% | $10.7m | 146,239 | 87% | added |
| 37 | TENX Tenax Therapeutics Inc | 0.4% | $7.3m | 500,039 | 379% | added | |
| 38 | SION Sionna Therapeutics Inc | Healthcare | 0.3% | $6.4m | 144,432 | – | new |
| 39 | ABSI Absci Corporation | Healthcare | 0.2% | $3.9m | 337,400 | – | new |
| 40 | MIRM Mirum Pharmaceuticals Inc | Healthcare | 0.2% | $3.2m | 27,591 | 0% | held |
| 41 | JBIO Jade Biosciences Inc | Healthcare | 0.1% | $2.4m | 107,391 | 0% | held |
| 42 | SVRA Savara Inc | Healthcare | 0.1% | $2.2m | 364,763 | 0% | held |
| 43 | PRAX Praxis Precision Medicines I | Healthcare | 0.1% | $2.2m | 6,440 | -90% | reduced |
| 44 | SEPN Septerna Inc | Healthcare | 0.1% | $1.6m | 47,506 | 0% | held |
| 45 | OKUR Onkure Therapeutics Inc | 0.1% | $1.5m | 321,692 | 127% | added | |
| 46 | SGMT Sagimet Biosciences Inc | Healthcare | 0.1% | $1.3m | 166,667 | – | new |
| 47 | WVE Wave Life Sciences Ltd | Healthcare | 0.1% | $1.1m | 189,253 | 0% | held |
| 48 | AKTS Aktis Oncology Inc | 0.1% | $1.0m | 32,436 | – | new | |
| 49 | TYRA Tyra Biosciences Inc | Healthcare | 0.1% | $1.0m | 32,267 | -84% | reduced |
| 50 | BOLT Bolt Biotherapeutics Inc | 0.0% | $530.2k | 137,721 | 0% | held |
What did Sofinnova Investments, Inc. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| AZN AstraZeneca PLC | 27.5% | $89.9m |
| BIIB Biogen Inc | 12.9% | $42.1m |
| CELC Celcuity Inc | 12.8% | $41.8m |
| BBIO BridgeBio Pharma Inc | 9.3% | $30.4m |
| DXCM Dexcom Inc | 7.6% | $24.7m |
| XENE Xenon Pharmaceuticals Inc | 5.4% | $17.7m |
| SYK Stryker Corporation | 4.5% | $14.6m |
| ROIV Roivant Sciences Ltd | 4.1% | $13.2m |
| CMPX Compass Therapeutics Inc | 3.3% | $10.9m |
| ORIC Oric Pharmaceuticals Inc | 2.6% | $8.6m |
| TNGX Tango Therapeutics Inc | 2.5% | $8.3m |
| AXGN AxoGen Inc | 2.1% | $7.0m |
| CYTK Cytokinetics Inc | 1.9% | $6.0m |
| HRMY Harmony Biosciences Hldgs Inc | 1.3% | $4.3m |
| PCVX Vaxcyte Inc | 0.9% | $2.9m |
| ESTA Establishment Labs Hldgs Inc | 0.6% | $1.9m |
| ACAD Acadia Pharmaceuticals Inc | 0.5% | $1.7m |
| SLNOEUR Soleno Therapeutics Inc | 0.2% | $491.8k |
| ZYME Zymeworks Inc | 0.0% | $40.3k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 87.4% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Sofinnova Investments, Inc.'s portfolio?
Across every quarter Sofinnova Investments, Inc. has filed, its median largest position is 19.0% of the book and its median top-ten weight is 57.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 19.0 completed holding spells, the median lasted 1.0 quarters; 53.0 positions are still open and their final length is unknown.